APA

Dredge K., Horsfall R., Robinson S. P., Zhang L., Lu L., Tang Y., Shirley M. A., Muller G., Schafer P., Stirling D., Dalgleish A. G. & Bartlett J. B. (20050804). Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. : Microvascular research.

Chicago

Dredge Keith, Horsfall Rebecca, Robinson Simon P, Zhang Ling-Hua, Lu Ling, Tang Yang, Shirley Michael A, Muller George, Schafer Peter, Stirling David, Dalgleish Angus G and Bartlett J Blake. 20050804. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. : Microvascular research.

Harvard

Dredge K., Horsfall R., Robinson S. P., Zhang L., Lu L., Tang Y., Shirley M. A., Muller G., Schafer P., Stirling D., Dalgleish A. G. and Bartlett J. B. (20050804). Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. : Microvascular research.

MLA

Dredge Keith, Horsfall Rebecca, Robinson Simon P, Zhang Ling-Hua, Lu Ling, Tang Yang, Shirley Michael A, Muller George, Schafer Peter, Stirling David, Dalgleish Angus G and Bartlett J Blake. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. : Microvascular research. 20050804.